New Delhi [India], May 2 (ANI): The COVID-19 working group of the National Technical Advisory Group on Immunisation (NTAGI) will review the data of COVID-19 vaccines for the children aged 5 to 12 years on May 4, said sources on Monday.
"After looking into the safety and efficacy data of the vaccines, the second level Standing Technical Sub-Committee (STSC) will review and discuss the recommendations by the working group. The STSC will again review the data and then give their decision to the final group of NTAGI that will take the final call," said sources.
Recently, the Drugs Controller General of India (DCGI) granted emergency use authorization to Biological E's Corbevax for children in the age bracket of 5 to 12 years and Bharat Biotech's Covaxin for kids aged 6 to 12 years.
Last week, NTAGI approved the Serum Institute of India's COVID-19 vaccine Covovax for the age group 12-17.
This comes after Prime Minister Narendra Modi stressed that vaccination for all eligible children at the earliest with "special campaigns" in schools is a priority for the government.
Covovax has already been approved by the Drugs Controller General of India (DCGI) for children above 12 years of age, but its administration has not been allowed yet.
COVID-19 vaccination for minors in India started from January 3 onwards for those in the 15-18 age group with Bharat Biotech's Covaxin. The drive later expanded on March 16 to include children aged above 12 for Corbevax. India is currently administering two COVID-19 vaccines for children above 12.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU